The TCR field continues to rely on a protracted preclinical selection process, which utilizes conventional assays such as affinity and peptide titrations that correlate poorly with T-cell functionality. Optimal TCR selection necessitates thorough preclinical characterization, prompting Carr et al., to focus on comprehensive cell-cell binding assessment to enhance preclinical decision-making.
Julian Ashby25 June 2024
